# NAMS catalysts: NewAmsterdam Pharma Co N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nams/catalysts

> NewAmsterdam Pharma Co N.V. (NAMS) has 6 upcoming catalysts. The next is the obicetrapib primary completion, November 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | NewAmsterdam Pharma Co N.V. |
| Ticker | NAMS (Nasdaq) |
| SEC CIK | 1936258 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nams |

## Cash runway

Cash $643.1M as of 2026-09-30; quarterly burn $39.8M; about 48.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-446228).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [Obicetrapib trial start](https://sec-api.dev/pdufa/obicetrapib) | NAMS |  | completed | "The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-ex99_1.htm)) |
| Jul 2024 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS |  | completed, met | "We announced topline results for BROOKLYN in July 2024 and for BROADWAY in December 2024, both of which met the primary endpoint for the study with safety and tolerability comparable to placebo." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm)) |
| Q4 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | scheduled | "NewAmsterdam completed enrollment of over 2,500 patients in July 2023 and expects to report topline data in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312524262125/d868860dex991.htm)) |
| Nov 2024 | [Obicetrapib trial start](https://sec-api.dev/pdufa/obicetrapib) | NAMS | HeFH, ASCVD or ASCVD risk equivalents | completed | "Based on the results of this pilot bioequivalence trial and the data and learnings from our ROSE2 trial, we selected a formulation for an FDC tablet of obicetrapib and ezetimibe and initiated TANDEM, a Phase 3 pivotal trial, to evaluate 10 mg obicetrapib and 10 mg ezetimibe as an FDC used as an adjunct to diet and maximally tolerated lipid-lowering therapies to potentially enhance LDL-C lowering in patients with HeFH, ASCVD or ASCVD risk equivalents, in the first quarter of 2024 and announced topline data in November 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm)) |
| November 20, 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "On November 20, 2024, we announced positive topline data from our Phase 3 TANDEM clinical trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| Dec 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "In December 2024, NewAmsterdam reported positive topline data from the BROADWAY trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025109567/nams-ex99_1.htm)) |
| December 10, 2024 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | established atherosclerotic cardiovascular disease | completed, positive | "On December 10, 2024, we announced positive topline data from our Phase 3 BROADWAY clinical trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| December 31, 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "During the year ended December 31, 2024 the Company announced positive topline results from its Phase 3 BROOKLYN and BROADWAY clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| February 26, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-ex99_1.htm)) |
| May 8, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/nams-ex99_1.htm)) |
| Jun 2025 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "In June 2025, NewAmsterdam announced positive topline data from the prespecified AD biomarker analysis in the BROADWAY clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/nams-ex99_1.htm)) |
| June 9, 2025 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimers Disease (AD) biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/d74901dex991.htm)) |
| Aug 2025 | [Obicetrapib NDA/BLA acceptance](https://sec-api.dev/pdufa/obicetrapib) | NAMS |  | completed | "Other than our submission to the EMA and the EMA's acceptance of MAAs for review for obicetrapib in August 2025, we have not previously submitted an NDA, an MAA or any similar drug approval filing to the FDA, the EMA or any comparable regulatory authority for any product candidate, and we cannot be certain that obicetrapib will be successful in clinical trials or receive regulatory approval." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm)) |
| August 6, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/nams-ex99_1.htm)) |
| November 5, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm)) |
| February 18, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-ex99_1.htm)) |
| May 7, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-ex99_1.htm)) |
| August 5, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm)) |
| September 2026 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Antioxidant Absorption | delayed | "NCT06982508 (Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06982508)) |
| Sep to Dec 2026 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Antioxidant Absorption | scheduled | "NCT06982508 (Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06982508)) |
| November 2026 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05202509 (Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05202509)) |
| Nov 2026 to Feb 2027 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05202509 (Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05202509)) |
| November 2026 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Dyslipidemias | scheduled | "NCT06496243 (Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496243)) |
| Nov 2026 to Feb 2027 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Dyslipidemias | scheduled | "NCT06496243 (Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496243)) |
| November 2027 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic | scheduled | "NCT06305559 (A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305559)) |
| Nov 2027 to Feb 2028 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic | scheduled | "NCT06305559 (A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305559)) |
| March 2028 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS) | scheduled | "NCT07219602 (A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219602)) |
| Mar to Jun 2028 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS) | scheduled | "NCT07219602 (A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219602)) |
| September 2028 | [Obicetrapib primary completion](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Preclinical Alzheimer's Disease | scheduled | "NCT07794670 (Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794670)) |
| Sep to Dec 2028 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | Preclinical Alzheimer's Disease | scheduled | "NCT07794670 (Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794670)) |

## Drugs

- [Obicetrapib](https://sec-api.dev/pdufa/obicetrapib): hefh, ascvd or ascvd risk equivalents, hefh, ascvd or ascvd risk equivalent patients, type 2 diabetes or metabolic syndrome, established atherosclerotic cardiovascular disease, Lipidemia, Dyslipidemias, Atherosclerotic Cardiovascular Disease, Antioxidant Absorption

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nams/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NAMS catalysts: NewAmsterdam Pharma Co N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nams/catalysts

```bibtex
@misc{secapidev_companies_nams_catalysts_20261116,
  title        = {NAMS catalysts: NewAmsterdam Pharma Co N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nams/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nams_catalysts_20261116","title":"NAMS catalysts: NewAmsterdam Pharma Co N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nams/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
